OR WAIT null SECS
July 02, 2024
The CRDMO will contribute cell discovery services that will benefit clinical development of novel technologies.
July 01, 2024
Following the evaluation, the company will decide whether it wants to move forward with the IDMO’s automated, end-to-end, cell therapy manufacturing platform.
The company’s latest investment—featuring new cGMP suites at its Devens, MA plant—is valued at $30 million.
June 28, 2024
The North Carolina project adds 1.4 million square feet of dedicated production space for aseptic manufacturing and finished production processes.
June 26, 2024
The agreement will look to further develop cell and gene therapies for the treatment of hematological cancers.
June 25, 2024
The Hopewell facility—which will serve as the CDMO’s North American hub—is expected to help accelerate the cell and gene therapy delivery process.
June 21, 2024
The partnership will offer an end-to-end manufacturing solution for biopharma companies.
June 20, 2024
The acquisition of the 87,000 square-foot Camden, MD plant provides the CDMO with the ability to offer clinical and commercial non-viral aseptic fill-finish services on four fill lines.
June 14, 2024
The contract manufacturer financially committed over $107 million into the facility, which can reportedly handle large-scale manufacturing of active ingredients based on messenger ribonucleic acid.
June 12, 2024
The 53,000 square-foot facility is expected to become a Northeastern biotech hub, and will be home to various CGT services.